Anti-PCSK9 antibody produced in goat, affinity isolated antibody, buffered aqueous solution

Not available outside of the UK & Ireland.

Biochem/physiol Actions

PCSK9 (proprotein convertase subtilisin/Kexin Type 9) promotes lysosomal degradation of LDLR (low density lipoprotein receptor), VLDL (very low density lipoprotein receptor) and LRP (LDL related protein) to cause clearance of plasma cholesterol. On the other hand, PCSK9 also stimulates the release of chylomicron in intestinal cells. Lower intracellular cholesterol and mutations such as gain of function stimulates the expression of PCSK9. Autosomal dominant hypercholesterolemia is a result of high LDLR-degradation caused due to mutated PCSK9. PCSK9 is known to prevent the entry and replication of hepatitis C virus. PCSK9 expression is observed in atherosclerotic plaques.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Features and Benefits

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

General description

PCSK9 (proprotein convertase subtilisin/Kexin Type 9) codes for a secretory serine protease predominantly expressed in liver and intestine. The PCSK9 gene is mapped to human chromosome 1p32.3 and is highly polymorphic.. PCSK9 is also expressed in vascular smooth muscle cells.

Immunogen

Peptide with sequence TRFHRQASKCDSHGT, from the internal region of the protein sequence according to NP_777596.2

Physical form

Supplied at 0.5 mg/mL in 20mM Tris (pH 7.3) and 150mM NaCl with 0.02% sodium azide and 0.5% bovine serum albumin.